{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T02:10:04Z","timestamp":1747793404986,"version":"3.41.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.japh.2025.102355","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T21:16:41Z","timestamp":1739567801000},"page":"102355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with atrial fibrillation"],"prefix":"10.1016","volume":"65","author":[{"given":"Anjana","family":"Mohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish A.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-8290","authenticated-orcid":false,"given":"Ekere James","family":"Essien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutugandha","family":"Paranjpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-4892","authenticated-orcid":false,"given":"Bilqees","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-8523","authenticated-orcid":false,"given":"Susan","family":"Abughosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2025.102355_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/heartjnl-2019-314898","article-title":"Stroke and thromboembolism prevention in atrial fibrillation","volume":"106","author":"Jame","year":"2020","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.chest.2018.03.040","article-title":"Atrial fibrillation in the ICU","volume":"154","author":"Bosch","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.japh.2025.102355_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.03.212","article-title":"Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke","volume":"215","author":"Alberts","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/jfcm.JFCM_99_18","article-title":"Stroke in atrial fibrillation: review of risk stratification and preventive therapy","volume":"26","author":"Alshehri","year":"2019","journal-title":"J. Family Community Med"},{"issue":"10","key":"10.1016\/j.japh.2025.102355_bib6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/clc.22294","article-title":"Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2 -VASc, R2 CHADS2, HAS-BLED, ATRIA, and more)","volume":"37","author":"Dzeshka","year":"2014","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/jth.13324","article-title":"The role of CHADS2 and CHA2 DS2 -VASc scores in the prediction of stroke in individuals without atrial fibrillation: a population-based study","volume":"14","author":"Saliba","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib8","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.japh.2025.102355_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.115.018172","article-title":"Systemic embolic events (SEE) in atrial fibrillation: SEEing embolic risk more clearly","volume":"132","author":"Chatterjee","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.japh.2025.102355_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.japh.2025.102355_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/CIRCULATIONAHA.114.013243","article-title":"Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes","volume":"132","author":"Bekwelem","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/europace\/eut001","article-title":"Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies","volume":"15","author":"Roskell","year":"2013","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.japh.2025.102355_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin Cardiol"},{"issue":"10","key":"10.1016\/j.japh.2025.102355_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.japh.2025.102355_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.japh.2025.102355_bib16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/pds.5317","article-title":"Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies","volume":"30","author":"van den Ham","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.japh.2025.102355_bib17","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bcp.14450","article-title":"Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation","volume":"87","author":"Souverein","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"10.1016\/j.japh.2025.102355_bib18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14779072.2019.1620600","article-title":"Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: a systematic review","volume":"17","author":"Mohan","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ahj.2014.03.023","article-title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration","volume":"167","author":"Shore","year":"2014","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.japh.2025.102355_bib22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/phar.1989","article-title":"Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation","volume":"37","author":"Manzoor","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.japh.2025.102355_bib23","first-page":"1054","article-title":"Adherence to a novel oral anticoagulant among patients with atrial fibrillation","volume":"21","author":"Zhou","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"10.1016\/j.japh.2025.102355_bib24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pds.4268","article-title":"Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study","volume":"26","author":"Maura","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003074","article-title":"Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.japh.2025.102355_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011427","article-title":"Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation","volume":"8","author":"Hernandez","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"Banerjee","year":"2020","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.japh.2025.102355_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"Borne","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.japh.2025.102355_bib29","doi-asserted-by":"crossref","first-page":"j4587","DOI":"10.1136\/bmj.j4587","article-title":"Handling time varying confounding in observational research","volume":"359","author":"Mansournia","year":"2017","journal-title":"BMJ"},{"issue":"suppl 2","key":"10.1016\/j.japh.2025.102355_bib30","doi-asserted-by":"crossref","first-page":"ii84","DOI":"10.1093\/ndt\/gfw341","article-title":"Marginal structural models in clinical research: when and how to use them?","volume":"32","author":"Williamson","year":"2017","journal-title":"Nephrol Dial Transplant"},{"author":"Crowson","key":"10.1016\/j.japh.2025.102355_bib31"},{"issue":"4","key":"10.1016\/j.japh.2025.102355_bib32","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/rth2.12221","article-title":"Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: a national retrospective study","volume":"3","author":"Wanat","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10157-020-01870-3","article-title":"Introduction to clinical research based on modern epidemiology","volume":"24","author":"Hoshino","year":"2020","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"10.1016\/j.japh.2025.102355_bib34","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s00198-017-4129-6","article-title":"Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data","volume":"28","author":"Xue","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.japh.2025.102355_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2167696815621645","article-title":"A Primer on inverse probability of treatment weighting and marginal structural models","volume":"4","author":"Thoemmes","year":"2015","journal-title":"Emergin Adulthood"},{"issue":"4","key":"10.1016\/j.japh.2025.102355_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.japh.2025.102355_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.japh.2025.102355_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022644","article-title":"Trends in anticoagulation prescription spending among medicare part D and Medicaid beneficiaries between 2014 and 2019","volume":"10","author":"Duvalyan","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.japh.2025.102355_bib39","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age","volume":"123","author":"Malik","year":"2019","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.japh.2025.102355_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021601","article-title":"Long-term medication adherence trajectories to direct oral anticoagulants and clinical outcomes in patients with atrial fibrillation","volume":"10","author":"An","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"suppl 1","key":"10.1016\/j.japh.2025.102355_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ijlh.12992","article-title":"An update on laboratory assessment for direct oral anticoagulants (DOACs)","volume":"41","author":"Gosselin","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/phar.1884","article-title":"Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know","volume":"37","author":"Conway","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.japh.2025.102355_bib43","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1185\/03007995.2015.1077213","article-title":"Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications","volume":"31","author":"Crivera","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.japh.2025.102355_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12872-019-1033-3","article-title":"Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?","volume":"19","author":"Pham","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.japh.2025.102355_bib45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/pop.2013.0056","article-title":"The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis","volume":"17","author":"Patel","year":"2014","journal-title":"Popul Health Manag"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40256-019-00371-3","article-title":"Adherence to anticoagulation and risk of stroke among medicare beneficiaries newly diagnosed with atrial fibrillation","volume":"20","author":"Hernandez","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.japh.2025.102355_bib47","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41598-022-07316-y","article-title":"Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation","volume":"12","author":"Yang","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.japh.2025.102355_bib48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/europace\/euz273","article-title":"The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients","volume":"22","author":"Kim","year":"2020","journal-title":"Europace"},{"issue":"11","key":"10.1016\/j.japh.2025.102355_bib49","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or Rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.japh.2025.102355_bib50","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/STROKEAHA.120.028825","article-title":"Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the Naxos study","volume":"51","author":"Van Ganse","year":"2020","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.japh.2025.102355_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/joim.13140","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the Aristophanes study","volume":"289","author":"Lip","year":"2021","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.japh.2025.102355_bib52","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, Rivaroxaban, and Apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.japh.2025.102355_bib53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCEP.111.967000","article-title":"Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation","volume":"5","author":"Gallego","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"10.1016\/j.japh.2025.102355_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1753944716663156","article-title":"Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice","volume":"11","author":"Shah","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:37:04Z","timestamp":1747791424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319125000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1544319125000342"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102355","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102355"}}